Article
Oncology
Mirco Bartolomei, Alfredo Berruti, Massimo Falconi, Nicola Fazio, Diego Ferone, Secondo Lastoria, Giovanni Pappagallo, Ettore Seregni, Annibale Versari
Summary: International guidelines on the management of neuroendocrine neoplasms provide a solid foundation, but expert opinion remains important due to limited clinical evidence and the diverse nature of NENs. A group of experts formulated 14 statements addressing controversial issues in diagnosis and treatment, covering a wide range of topics from initial prognosis to personalized therapeutic approaches.
Review
Cardiac & Cardiovascular Systems
Nicky Janssen, Jean H. T. Daemen, Elise J. van Polen, Nadine A. Coorens, Yanina J. L. Jansen, Aimee J. P. M. Franssen, Karel W. E. Hulsewe, Yvonne L. J. Vissers, Frank -Martin Haecker, Jose R. Milanez de Campos, Erik R. de Loos, Chest Wall Int Grp Collaborator Grp
Summary: This study aims to evaluate the consensus and controversies regarding the diagnostic protocol, indications for surgical correction, and postoperative evaluation of pectus excavatum. Through multiple rounds of survey, consensus was reached on certain topics, aiding in the standardization of pectus excavatum care.
ANNALS OF THORACIC SURGERY
(2023)
Review
Medicine, General & Internal
Mia Bierbaum, Frances Rapport, Gaston Arnolda, Yvonne Tran, Brona Nic Giolla Easpaig, Kristiana Ludlow, Jeffrey Braithwaite
Summary: This paper presents a protocol for a systematic review aiming to determine cancer treatment CPG adherence rates in Australia across various common cancers and to identify factors associated with adherence.
Article
Endocrinology & Metabolism
Ricardo Correa, Joanna Miragaya, David A. Cohen, Thanh D. Hoang, Sina Jasim, David C. Lieb, Sandra L. Weber, Melanie D. Bird, Carla Stec
Summary: This 2023 updated protocol summarizes AACE's new framework for the development of clinical practice guidelines and other guidance documents, which includes changes to methodology, processes, and policies. AACE has reviewed its development processes for guidance documents against recognized standards and made improvements. The new framework incorporates various changes and enhancements to ensure the quality and reliability of the content.
ENDOCRINE PRACTICE
(2023)
Review
Clinical Neurology
Ya-Xin Chen, Ning Liang, Xiao-Ling Li, Si-Hong Yang, Yan-Ping Wang, Nan-Nan Shi
Summary: This study compared and harmonized recommendations for the diagnosis and treatment of Mild Cognitive Impairment (MCI) based on current clinical practice guidelines. Neuropsychological testing and biomarker assessments were common recommendations for MCI diagnosis, while there were differing opinions on pharmacological interventions. Non-pharmacological interventions like physical activity and cognitive interventions were widely recommended. More research is needed on the diagnosis and treatment of MCI.
FRONTIERS IN NEUROLOGY
(2021)
Article
Clinical Neurology
Jessica Ailani, Rebecca C. Burch, Matthew S. Robbins
Summary: This update aims to incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute and preventive treatments for migraine in adults. It provides practical recommendations based on expanded evidence base and emerging expert consensus, in the absence of a formal guideline.
Review
Medicine, General & Internal
Yue Zhang, Yu-Xi Li, Dong-Ling Zhong, Xiao-Bo Liu, Yuan-Yuan Zhu, Rong-Jiang Jin, Juan Li
Summary: This systematic review aims to assess the quality of guidance documents, evaluate the recommendations for rehabilitation assessments and therapies for COVID-19, and provide reasonable suggestions. It will serve as a quick reference for front-line clinicians, therapists, and patients and provide valuable insights for future guidelines.
Article
Orthopedics
Deepa Jeevanantham, Venkadesan Rajendran, Zachary McGillis, Line Tremblay, Celine Lariviere, Andrew Knight
Summary: This guideline provides recommendations for physical therapists managing multiple myeloma patients based on physiological markers, complete patient presentation, and the stage of medical treatment. Developed through a systematic review and consensus process, these guidelines aim to optimize rehabilitation outcomes by filling an important knowledge gap in the field.
Review
Oncology
Giovanni Corso, Francesca Magnoni
Summary: Scientific research on the risk of breast cancer in the context of hereditary breast cancer syndrome is constantly evolving, requiring a multidisciplinary approach based on updated guidelines. The recent Expert Panel Consensus provides accurate treatment directions for patients with specific genetic mutations, serving as a valuable tool for physicians in daily practice.
EUROPEAN JOURNAL OF CANCER PREVENTION
(2021)
Article
Oncology
Teresa L. Deshields, Sharla Wells-Di Gregorio, Stacy R. Flowers, Kelly E. Irwin, Ryan Nipp, Lynne Padgett, Brad Zebrack
Summary: Effective distress management for cancer patients has many benefits, but due to various barriers, many distressed patients do not receive the needed services. The Consolidated Framework for Implementation Research outlines key challenges and facilitators in implementing distress management, providing evidence-based strategies and interventions to address these barriers and challenges.
CA-A CANCER JOURNAL FOR CLINICIANS
(2021)
Review
Medicine, General & Internal
Esther J. van Zuuren, Patricia Logullo, Amy Price, Zbys Fedorowicz, Ellen L. Hughes, William T. Gattrell
Summary: This systematic review examined the reporting quality of consensus methodology and identified potential checklist items for the development of a consensus reporting guideline in the ACCORD project. The majority of studies indicated that the quality of reporting could be improved, and common items addressed were consensus panel composition and definition of consensus. The least addressed items included public patient involvement, the role of the steering committee, and conflict of interest.
Review
Immunology
Rachel M. Reeves, Maarten van Wijhe, Toni Lehtonen, Luca Stona, Anne C. Teirlinck, Liliana Vazquez Fernandez, You Li, Richard Osei-Yeboah, Thea K. Fischer, Terho Heikkinen, Michiel van Boven, Hakon Boas, Daniele Dona, Elisa Barbieri, Harry Campbell
Summary: This systematic review aimed to identify clinical practice guidelines (CPGs) for the prevention of respiratory syncytial virus (RSV) infection across Europe. The study found discrepancies in recommendations for palivizumab prophylaxis for premature infants and children with various diseases. The study recommends that agencies adopt the RIGHT reporting requirements to improve the presentation of evidence-based decisions.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Oncology
Anna C. Pavlick, Charlotte E. Ariyan, Elizabeth Buchbinder, Diwakar Davar, Geoffrey T. Gibney, Omid Hamid, Tina J. Hieken, Benjamin Izar, Douglas B. Johnson, Rajan P. Kulkarni, Jason J. Luke, Tara C. Mitchell, Meghan J. Mooradian, Krista M. Rubin, April K. S. Salama, Keisuke Shirai, Janis M. Taube, Hussein A. Tawbi, J. Keith Tolley, Caressa Valdueza, Sarah A. Weiss, Michael K. Wong, Ryan J. Sullivan
Summary: Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has greatly transformed the treatment landscape of this chemotherapy-resistant disease. Combination regimens have gained regulatory approvals for the treatment of metastatic cutaneous melanoma, with the possibility of cure for some patients. However, traditional immunotherapy biomarkers have failed to predict response reliably and ICIs are associated with unique toxicity profiles. The clinical practice guideline on immunotherapy aims to provide guidance for healthcare professionals and improve patient care.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Julie R. Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, Jill Brufsky, Laura C. Cappelli, Frank B. Cortazar, David E. Gerber, Lamya Hamad, Eric Hansen, Douglas B. Johnson, Mario E. Lacouture, Gregory A. Masters, Jarushka Naidoo, Michele Nanni, Miguel-Angel Perales, Igor Puzanov, Bianca D. Santomasso, Satish P. Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A. Sosman, Michelle Turner, Marc S. Ernstoff
Summary: ICIs are standard treatments for cancer, but come with risks of immune-related adverse events. The SITC convened an expert panel to develop guidelines for managing irAEs, aiming to improve patient outcomes through evidence-based recommendations.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Ronan J. Kelly, Katherine Bever, Joseph Chao, Kristen K. Ciombor, Cathy Eng, Marwan Fakih, Lipika Goyal, Joleen Hubbard, Renuka Iyer, Holly T. Kemberling, Smitha Krishnamurthi, Geoffrey Ku, Mindy Mintz Mordecai, Van K. Morris II, Andrew Scott Paulson, Valerie Peterson, Manish A. Shah, Dung T. Le
Summary: Gastrointestinal (GI) cancers are a heterogeneous group of malignancies that impose a significant burden globally. Immunotherapy, specifically immune checkpoint inhibitors (ICIs), has transformed the treatment landscape for several GI cancers. However, ICIs have differing biomarker and histology requirements depending on the anatomic site of origin, and they are associated with unique toxicity profiles. To provide guidance to the oncology community, the Society for Immunotherapy of Cancer (SITC) developed a clinical practice guideline on immunotherapy for GI cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Health Care Sciences & Services
Hsien Seow, Daryl Bainbridge, Kelli Stajduhar, Denise Marshall, Michelle Howard, Melissa Brouwers, Doris Barwich, Fred Burge, Mary Lou Kelley
Summary: CAPACITI is a virtual training program aimed at helping primary care providers offer early palliative care. An evaluation study found that CAPACITI can improve provider confidence in core competencies and potentially enhance palliative care capacity in primary care teams.
AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE
(2023)
Editorial Material
Oncology
Gary H. Lyman, Pavlos Msaouel, Nicole M. Kuderer
Summary: This article summarizes key considerations related to risk modeling in clinical oncology, including data quality, missing data, sample size estimation, and variable selection. The importance of rigorous internal validation and careful examination of model stability and quality is emphasized.
CANCER INVESTIGATION
(2023)
Article
Oncology
Funda Meric-Bernstam, James M. Ford, Peter J. O'Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin, Roisin E. O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gary H. Lyman, James Tricoli, David Patton, Stanley R. Hamilton, Robert J. Gray, Douglas S. Hawkins, Bhanumati Ramineni, Keith T. Flaherty, Petros Grivas, Timothy A. Yap, Jordan Berlin, James H. Doroshow, Lyndsay N. Harris, Jeffrey A. Moscow
Summary: In the past decade, there have been multiple trials to determine the effectiveness of treating cancer based on specific genomic alterations. However, most patients do not respond to single-agent therapies targeting a single alteration, and drug resistance often develops. To address this, the NCI has developed NCI-ComboMATCH, a study to explore genomically-directed combination therapies and overcome drug resistance.
CLINICAL CANCER RESEARCH
(2023)
Review
Medical Laboratory Technology
Eyal Podolsky, Natasha Hudek, Christopher McCudden, Justin Presseau, Sezgi Yanikomeroglu, Melissa Brouwers, Jamie C. C. Brehaut
Summary: This scoping review investigates the factors and processes that developers report using to inform decisions about what tests to target for practice improvement. From 114 eligible studies, 30 factors related to test choice and nine processes used to inform decisions were identified.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Correction
Surgery
Stavros A. Antoniou, Ivan D. Florez, Sheraz Markar, Patricia Logullo, Manuel Lopez-Cano, Gianfranco Silecchia, George A. Antoniou, Sofia Tsokani, Dimitrios Mavridis, Melissa Brouwers
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2023)
Editorial Material
Oncology
Gary H. Lyman
CANCER INVESTIGATION
(2023)
Article
Oncology
Ramon Mohanlal, Stephan Ogenstad, Gary H. Lyman, Lan Huang, Douglas W. Blayney
Summary: Neutropenia caused by myelosuppressive cancer chemotherapy is a significant toxicity, and grade 4 neutropenia (Gr4N) is a measure of its severity. Through a meta-analysis, we found that the incidence of Gr4N is closely correlated with febrile neutropenia (FN), days of severe neutropenia (DSN), and nadir absolute neutrophil count (ANC), all of which are important predictors of morbidity. By setting a threshold of 65% for Gr4N, the risks of FN and DSN were below the levels for adverse CIN outcomes. Gr4N is highly predictive for adverse CIN outcomes, and a 65% threshold distinguishes between low and high risks for FN and other adverse CIN outcomes.
CANCER INVESTIGATION
(2023)
Review
Oncology
Maryam B. Lustberg, Nicole M. Kuderer, Aakash Desai, Cristiane Bergerot, Gary H. Lyman
Summary: Despite the lack of systematic efforts, this review provides a comprehensive analysis of the most common long-term and late adverse events associated with chemotherapy and other anticancer treatments. It discusses the underlying mechanisms, management strategies, and clinical practice guidelines for these adverse events. Additionally, it highlights the need for effective management of treatment-related events in oncology.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Article
Oncology
Brian Bourbeau, Gary H. Lyman, Xiudong Jennifer Lei, Lee Jones, Jon Rosenthal, Mary May Kozlik, Kurt R. Oettel, Alfred Tinger, Ray Page
Summary: Biosimilars have increased in usage over the past 3 years, with utilization rates ranging from 51% to 80% depending on the specific biologic. Independent physician practices had higher utilization of biosimilars for certain biologics, while Medicaid plans and traditional Medicare had lower utilization rates compared to commercial health plans. The average cost per dose decreased by 24% to 41% for the studied biologics.
JCO ONCOLOGY PRACTICE
(2023)
Article
Oncology
Gladys Rodriguez, Joan Mancuso, Gary H. Lyman, Fatima Cardoso, Zeina Nahleh, Julie M. Vose, Julie R. Gralow, Michael Francisco, Shimere Sherwood
Summary: ASCO has taken steps to raise awareness about biosimilar products and published a statement in 2018 to provide guidance on their use in oncology. The FDA has approved a significant number of biosimilar products for use in the United States, including those for cancer treatment. The recent approval of interchangeable biosimilar products for various diseases has further expanded the market. This policy statement by ASCO proposes recommendations on value, interchangeability, clinician barriers, and patient education and access to guide their future activities.
JCO ONCOLOGY PRACTICE
(2023)
Editorial Material
Oncology
Gary H. Lyman, Christopher H. Lyman, Nicole M. Kuderer
CANCER INVESTIGATION
(2023)
Editorial Material
Oncology
Gary H. Lyman, Christopher H. Lyman, Nicole M. Kuderer
CANCER INVESTIGATION
(2023)
Editorial Material
Oncology
Gary H. Lyman
CANCER INVESTIGATION
(2023)
Editorial Material
Oncology
Gary H. Lyman, Nicole M. Kuderer
CANCER INVESTIGATION
(2023)
Editorial Material
Oncology
Gary H. Lyman, Christopher H. Lyman, Nicole M. Kuderer
CANCER INVESTIGATION
(2023)